These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 31747323)

  • 1. GAPPS (Grading and Assessment of Pharmacokinetic-Pharmacodynamic Studies) a critical appraisal system for antimicrobial PKPD studies - development and application in pediatric antibiotic studies.
    Gastine S; Rashed AN; Hsia Y; Jackson C; Barker CIS; Mathur S; Tomlin S; Lutsar I; Bielicki J; Standing JF; Sharland M
    Expert Rev Clin Pharmacol; 2019 Dec; 12(12):1091-1098. PubMed ID: 31747323
    [No Abstract]   [Full Text] [Related]  

  • 2. Pediatric pharmacokinetics of the antibiotics in the access and watch groups of the 2019 WHO model list of essential medicines for children: a systematic review.
    Rashed AN; Jackson C; Gastine S; Hsia Y; Bielicki J; Standing JF; Tomlin S; Sharland M
    Expert Rev Clin Pharmacol; 2019 Dec; 12(12):1099-1106. PubMed ID: 31760892
    [No Abstract]   [Full Text] [Related]  

  • 3. Semi-mechanistic pharmacokinetic-pharmacodynamic modelling of antibiotic drug combinations.
    Brill MJE; Kristoffersson AN; Zhao C; Nielsen EI; Friberg LE
    Clin Microbiol Infect; 2018 Jul; 24(7):697-706. PubMed ID: 29229429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Children in clinical trials: towards evidence-based pediatric pharmacotherapy using pharmacokinetic-pharmacodynamic modeling.
    Brussee JM; Calvier EA; Krekels EH; Välitalo PA; Tibboel D; Allegaert K; Knibbe CA
    Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1235-44. PubMed ID: 27269200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotic dosing in children in Europe: can we grade the evidence from pharmacokinetic/pharmacodynamic studies - and when is enough data enough?
    Barker CI; Standing JF; Turner MA; McElnay JC; Sharland M
    Curr Opin Infect Dis; 2012 Jun; 25(3):235-42. PubMed ID: 22517604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs.
    Nielsen EI; Friberg LE
    Pharmacol Rev; 2013 Jul; 65(3):1053-90. PubMed ID: 23803529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic/pharmacodynamic models for time courses of antibiotic effects.
    Minichmayr IK; Aranzana-Climent V; Friberg LE
    Int J Antimicrob Agents; 2022 Sep; 60(3):106616. PubMed ID: 35691605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic-Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance.
    Germovsek E; Barker CIS; Sharland M; Standing JF
    Clin Pharmacokinet; 2019 Jan; 58(1):39-52. PubMed ID: 29675639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative clinical pharmacology practice for optimal use of antibiotics during the neonatal period.
    Samardzic J; Allegaert K; Wilbaux M; Pfister M; van den Anker JN
    Expert Opin Drug Metab Toxicol; 2016; 12(4):367-75. PubMed ID: 26817821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic modeling and simulation for dose rationale of doripenem in neonates and infants.
    Matsuo Y; Matsumoto S; Wajima T; Matsubara K
    Drug Metab Pharmacokinet; 2020 Feb; 35(1):145-150. PubMed ID: 31969257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of five paediatric dosing guidelines for antibiotics.
    Mathur S; Jackson C; Urus H; Ziarko I; Goodbun M; Hsia Y; Ellis S; Sharland M
    Bull World Health Organ; 2020 Jun; 98(6):406-412F. PubMed ID: 32514214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pharmacokinetic-pharmacodynamic (PKPD) model based on in vitro time-kill data predicts the in vivo PK/PD index of colistin.
    Khan DD; Friberg LE; Nielsen EI
    J Antimicrob Chemother; 2016 Jul; 71(7):1881-4. PubMed ID: 26983860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can a pharmacokinetic/pharmacodynamic (PKPD) model be predictive across bacterial densities and strains? External evaluation of a PKPD model describing longitudinal in vitro data.
    Nielsen EI; Khan DD; Cao S; Lustig U; Hughes D; Andersson DI; Friberg LE
    J Antimicrob Chemother; 2017 Nov; 72(11):3108-3116. PubMed ID: 28961946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding and applying pharmacometric modelling and simulation in clinical practice and research.
    Standing JF
    Br J Clin Pharmacol; 2017 Feb; 83(2):247-254. PubMed ID: 27567102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous Antibiotic and Antifungal Agent Pharmacokinetic-Pharmacodynamic Dosing in Adults with Severe Burn Injury.
    Cota JM; FakhriRavari A; Rowan MP; Chung KK; Murray CK; Akers KS
    Clin Ther; 2016 Sep; 38(9):2016-31. PubMed ID: 27586127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology.
    Barker CI; Germovsek E; Hoare RL; Lestner JM; Lewis J; Standing JF
    Adv Drug Deliv Rev; 2014 Jun; 73(100):127-39. PubMed ID: 24440429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing Clinical Outcomes Through Rational Dosing Strategies: Roles of Pharmacokinetic/Pharmacodynamic Modeling Tools.
    Chua HC; Tam VH
    Open Forum Infect Dis; 2022 Dec; 9(12):ofac626. PubMed ID: 36540388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics in antibiotic dose optimization.
    Sy SK; Zhuang L; Derendorf H
    Expert Opin Drug Metab Toxicol; 2016; 12(1):93-114. PubMed ID: 26652832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling.
    Admiraal R; van Kesteren C; Boelens JJ; Bredius RG; Tibboel D; Knibbe CA
    Arch Dis Child; 2014 Mar; 99(3):267-72. PubMed ID: 24356807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients.
    Zobell JT; Stockmann C; Young DC; Cash J; McDowell BJ; Korgenski K; Sherwin CM; Spigarelli M; Chatfield BA; Ampofo K
    Clin Ther; 2011 Nov; 33(11):1844-50. PubMed ID: 22018680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.